OREANDA-NEWS. April 23, 2015. Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the AACR Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015.  Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy.

Our Virtual Tumour platform has been extended to model immunomodulatory agents, currently a significant focus of cancer research. This extension captures the mechanisms by which immune checkpoint inhibitors activate the antitumor immune response and synergizes with other anticancer therapies. In this poster, through a preclinical case study we demonstrate that the extended Virtual Tumour can be applied to model the efficacy of such immune-checkpoint blockers, both alone and in combination with irradiation. The model predictions were validated against published experimental data, and found to accurately reflect the synergy of the combination treatment.

The abstract ("Modeling synergistic anti-PD-1 immunotherapy combinations with virtual tumor", No 4866) will be presented in the "Methods and Tools in Computational Cancer Biology" poster session, scheduled 8:00 AM-12:00 PM, 22 April 2015.